More to come from PARP drugs, says biotech CEO after strikin...

Five years AstraZeneca became an oncology trailblazer by getting the first PARP inhibitor class drug Lynparza, approved by the FDA for certain ovarian cancers.

Keytruda combo cleared as first-line kidney cancer treatment...

BI signs KRAS deal with India's Lupin, as pharma awaits key ...

Boehringer Ingelheim has signed a deal with India’s Lupin to develop and market a potential cancer drug targeting tumours driven by the KRAS mutation.

AZ gets China nod for Tagrisso in first-line lung cancer

Immunicum shares fall despite “fantastic” kidney cancer data

Tecentriq beats rivals to EU breast cancer market